3 results about "Scid mice" patented technology

This invention provides an irinotecan-conjugated polypeptide compound, its preparation method, and its application, belonging to the field of biomedical technology. Irinotecan (Dxd) is the active pharmaceutical ingredient. Irinotecan belongs to the topoisomerase I inhibitor class—camptothecin derivatives—and is a semi-synthetic small molecule chemotherapeutic drug capable of directly killing cancer cells in the active division phase and inhibiting tumor growth. TYLCTACDYTHH is a highly effective PDPN-targeting peptide that can effectively target the PDPN site in human glioblastoma. In vitro and in vivo experimental results show that the conjugated compound of this invention can significantly inhibit the proliferation of primary glioblastoma cells and effectively inhibit the growth of intracranial orthotopic xenografts in NOD-SCID mice, demonstrating good anti-tumor activity. This compound shows promise for targeted therapy of glioblastoma and has the potential to prolong patient survival.

This invention relates to the field of biomedical technology, and in particular to the application of hD1R protein in the preparation of drugs for the treatment of AML. Addressing the current lack of systematic and in-depth research on whether hD1R protein can directly act on AML cells and whether it has a synergistic effect with existing standard chemotherapy drugs (such as anthracyclines), this invention, through a series of in vivo and in vitro experiments and the construction of a NOD / SCID mouse transplantation model, confirms that hD1R protein alone can effectively inhibit AML cell proliferation, induce apoptosis, inhibit AML cell colony formation, and downregulate the expression of the key anti-apoptotic gene Bcl2 in AML cells. It also confirms that hD1R treatment can significantly prolong the survival of model mice. Furthermore, by setting up a Dox+hD1R group (combined experimental group), it is confirmed that when hD1R protein is used in combination with anthracycline chemotherapy drugs, it exhibits significant synergistic effects in inhibiting AML cell proliferation, promoting AML cell apoptosis, downregulating the expression of the anti-apoptotic gene Bcl2 in AML cells, and inhibiting AML cell colony formation.

The invention belongs to the technical field of medicines, discloses application of a compound CA3 in inhibiting leukemia cell proliferation and treating leukemia, and particularly discloses application of the compound CA3 shown as a formula (I) in treating leukemia. Pharmacological experiments prove that the CA3 can obviously inhibit the proliferation of leukemia cells HL-60 (the IC50 value is 5.4 * 10 <-7 > M); the tumor volume of an HL-60 cell ectopic transplantation NOD-SCID mouse is reduced 11 days after the CA3 is administered, and the tumor weight of the HL-60 cell ectopic transplantation NOD-SCID mouse is reduced 14 days after the CA3 is administered. Experimental results show that the CA3 significantly inhibits leukemia cell proliferation at a cellular level and significantly reduces leukemia tumor growth at an animal level.